


CRC1479 Symposium

Oncogene driven immune escape

July 10-12, 2024 | University Building KG1, Freiburg (Germany)



The first International CRC1479 Symposium will cover the newest developments in the topic of "Oncogene driven immune escape", following the concept, that oncogenic signaling can enable cancer cells to evade natural immune surveillance and immunotherapy. We are looking forward to an exciting symposium with presentations by leading experts of the field and short talks by successful early career scientists.

We are very much looking forward to welcoming you here in the Black Forest!

Program

Day 1 July 10th, 2024

12:00 am - 02:00 pm Registration and Reception 02.00 pm - 06.20 pm Session I and Session II

07.30 pm - open end Speakers' Dinner (for invited guests only)

Day 2 July 11th, 2024

08.00 am - 08.30 am Reception

08.30 am - 07.00 pm Session III, IV, V and Postersession

08.00 pm Conference Dinner, Poster award ceremony and

Get-Together, Restaurant "Waldsee"

Day 3 July 12th, 2024

08.30 am - 09.00 am Reception

09.00 am - 12.40 pm Session VI and VII 12.45 pm Farewell Lunch



Keynote Speakers

- Dean Felsher (Stanford)
- Erika Pearce (Baltimore)
- Daniel Peeper (Amsterdam)
- Vijay Kumar Kuchroo (Boston)

Confirmed Guest Speakers

- Daniel Schramek (Toronto)
- Florian Perner (Hannover)

- Franziska Blaeschke (San Francisco)
- Karen Dixon (Basel)
- Luca Vago (Milano)
- Pavan Bachireddy (Houston)
- Petya Apostolova (Basel)
- Rouven Höfflin (Rehovot)
- Jan Böttcher (München)

Dear colleagues,

It is our pleasure to welcome you to our Symposium "Oncogene driven immune escape" organized by our Collaborative Research Center / SFB 1479 and its Integrated Research Training Group (IRTG) in Freiburg. The CRC 1479 is funded by the German research foundation and has the overarching concept that oncogenic signalling can enable cancer cells to evade natural immune surveillance and immunotherapy. We set out to achieve a better and broader understanding of the relationship between oncogenic signalling and immune escape by studying multiple oncogenic signalling events in diverse genetic cancer models, as well as in human tumours.

There were major achievements in the first funding period of this multidisciplinary research network such as the identification of a connection between the MDM2/p53 axis and immune responses against leukemia, which has led to a clinical trial, the observation that IDH mutations cause immunosuppressive myeloid cells in glioma, the role of IL-21 for immune checkpoint inhibitor function and the impact of ATF6 on immune cell metabolism in HCC, besides others.

We hope that these discoveries will open new avenues in basic and clinical translational research. This Symposium will cover these topics and give you the opportunity to debate the current concepts of oncogenic signaling and immune escape mechanisms at the beautiful venue of the old University Building (KG1) in Freiburg.

We invite you to share your knowledge in scientific discussions to exchange thoughts and ideas.

From the organizers Robert Zeiser and Tilman Brummer



Day 1 July 10th, 2024

12.00 am to 2.00 pm Registration, Reception and snack

Session I: c-myc, ER stress and STING - key regulators of immune evasion? Chair: Robert Zeiser		
Time	Program point - talk	
2:00 pm	Welcome notes by Robert Zeiser (Freiburg)	
2:15 pm	KEYNOTE Lecture I by Dean Felsher (Stanford)	
	The MYC oncogene pathway is a global regulator of cancer growth and	
	immune evasion	
3:00 pm	Mathias Heikenwälder (Heidelberg/Tübingen)	
	Chronic activation turns the ER stress protein ATF6 into an oncoprotein	
	dictating immunotherapy response through metabolic reprogramming	
3:20 pm	Maike Hofmann (Freiburg)	
	ATF6α is a hepatic ER stress-inducing oncoprotein metabolically	
	restricting immunosurveillance - the human perspective	
3:40 pm	lan Frew (Freiburg)	
	Immunosuppressive crosstalk between tumour, myeloid and T cells in	
	an anti-PD-1/anti-CTLA-4 therapy resistant mouse ccRCC model	

4:0 pm to 4:30 pm **Coffee break**

Session II: Oncogenic drivers of leukemia immune Escape Chairs: Natalie Köhler, Robert Zeiser		
Time	Program point - talk	
4:30 pm	Petya Apostolova (Basel)	
•	Metabolic drivers of anti-leukemia immunity	
4:50 pm	Natalie Köhler (Freiburg)	
•	CMTM6 as a new player in leukemia immune escape	
5:10 pm	Robert Zeiser (Freiburg)	
-	Oncogene driven immune escape in AML	
5:30 pm	Justus Duyster (Freiburg)	
	Effects of oncogene-driven Oncostatin M in hematopoietic neoplasm	
5:50 pm	Pavan Bachireddy (Houston)	
	ASXL1 marks the spot: a story of suppression	
6:10 pm	Luca Vago (Milano)	
	Mechanisms of Leukemia Immune Escape after Transplant: From	
	Biology to Therapy (And Back)	

7:30 pm	Speakers Dinner - for invited guests only
	Hotel Rappen am Münsterplatz



Day 2 July 11th, 2024

8:00 am t	o 8:30 am Reception
Immune r	netabolism in cancer immunotherapy
Time	Program point - talk
8:30 am	Welcome notes to keynote lecture by Petya Apostolova
8:45 am	KEYNOTE Lecture II by Erika Pearce (Baltimore)
	Ordering Chaos: Delineating the Cell-Intrinsic Metabolic Signals that
	Regulate Immune Cell Differentiation

Session III: Oncogenic mutations and immune escape across entities Chairs: Tilman Brummer, Dietrich Ruess		
Time	Program point - talk	
9:30 am	Daniel Schramek (Toronto)	
	Decoding Aneuploidy: Identifying Drivers and Therapeutic Targets in	
	Basal-like Breast Cancer	
9:50 am	Florian Greten (Frankfurt)	
	Tumor-stroma crosstalk in colorectal cancer	
10:10 am	Florian Perner (Hannover)	
	TBA	
10:30 am	Lena Illert (Munich)	
	The role of the NPM-ALK / PD1 axis for transformation and	
	responsiveness of immunotherapy	

10:50	am to 11:30	Coffee brea	ık

Session IV: High resolution data analysis			
Chair: Mela	Chair: Melanie Börries		
Time	Program point - talk		
11:30 am	Marco Prinz (Freiburg)		
	The myeloid side of the brain		
11:50 am	Rouven Höfflin (Rehovot)		
	Spatial organization of the glioblastoma ecosystem		
12:10 pm	Geoffroy Andrieux (Freiburg)		
	Unveiling Oncogenic Landscapes: Spatial Resolution Informs Immune		
	Modulation and Precision Cancer Therapy		
12:30 pm	Tobias Wertheimer (Zürich)		
	Crosstalk between myeloid cells and Tregs supporting		
	immunosuppression in the TME		

12:50 pm to 2:30 pm Lunch break



4:55 pm

International Symposium July 10-12, 2024 - University of Freiburg, Aula Building KG I

Session V: Contribution of myeloid cells to oncogene-driven immune escape Chairs: lan Frew, Justus Duyster		
Start	Program point - talk	
2:30 pm	KEYNOTE Lecture III by Daniel Peeper (Amsterdam)	
	Function-based genomics to combat immunotherapy resistance	
3:15 pm	Nina Cabezas-Wallscheid (Freiburg)	
	Regulation of hematopoietic stem cell dormancy	
3:35 pm	Natascha Röhlen (Freiburg)	
	The role of cell junction and adhesion proteins for tumor progression	
	and immune escape in Hepatocellular carcinoma	
3:55 pm to	3:55 pm to 4:15 pm Coffee break	
4:15 pm	Olaf Groß (Freiburg)	
-	The Inflammasome in AML	
4:35 pm	Karen Dixon (Basel)	
•	Dendritic cell determinants of anti-tumour immunity	
	<u> </u>	

Poster Session	
5:30 pm to 7:00 pm	Poster Session with poster walk
•	Location: Waldsee; Waldseestraße 84; 79117 Freiburg

The role of PGE2-induced cDC1 dysfunction for tumor immune

Jan Böttcher (München)

escape



Day 3 July 12th, 2024:

0.00	1-0.00	
×·≺ııam	ith uilliam	RACANTIAN
ี บ.บบ ฉท	to 9:00 am	Reception

Session VI: Overcoming immune escape from cellular therapy Chairs: Susana Minguet, Robert Zeiser		
Start	Program point - talk	
9:00 am	Franziska Blaeschke (San Francisco)	
	Pooled CRISPR Knockin Screens: Reprogramming Therapeutic T	
	Cells	
9:30 am	Tobias Feuchtinger (Freiburg)	
	Immune-interaction in pediatric acute leukemia	
9:50 am	Susana Minguet (Freiburg)	
	From the basic mechanism of TCR activation to innovative	
	immunotherapies	

10:10 am to 10:40 **Coffee break** am

Session VII: Immune checkpoint molecules and T cell exhaustion Chair: Tobias Wertheimer, Kristina Maas-Bauer		
Start	Program point - talk	
10:40 am	KEYNOTE Lecture IV by Vijay Kumar Kuchroo (Boston)	
	Role of checkpoint molecule TIM-3 in regulating anti-tumor immunity	
11:25 am	Dietrich Ruess (Freiburg)	
	Interference with KRAS-signaling via combinatorial approaches	
	including PTPN11/SHP2-phosphatase inhibition to enhance anti-	
	tumour immunity in pancreatic cancer	
11:45 pm	Alexander Nyström (Freiburg)	
	Oncogenic HRAS promotes carcinoma progression through ECM	
	remodeling and immunosuppressive metabolites – prospect for	
	targeted therapies	
12:05 pm	Bertram Bengsch, Miriam Erlacher (Freiburg)	
	A cytokine explains the efficacy of CTLA-4 based checkpoint blockade	
	therapy in melanoma	

12:25 pm to 12:40 pm CLOSING REMARKS by Tilman Brummer, Robert Zeiser

12:45 pm Farewell Lunch
